An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals
Keri Losavio
Editor Keri Losavio has been a professional editor and writer in the medical and financial fields for 20 years and joined the Wiley team in February 2014. She has written for and edited newsletters, magazines, personal memoirs, book proposals, dissertations, textbooks and more.
ACR Convergence 2023 offers so much more than scientific sessions. If you have a special interest in a topic, this is the place to be. Consider these opportunities: Lab Tests Open Meeting Sunday, Nov. 12, 10–11 a.m. PST Location: Sapphire E Room, Hilton San Diego Bayfront Attendees interested in laboratory testing issues are invited to…
Science involves reading and writing as much as conducting experiments, says David S. Pisetsky, MD, PhD. No matter what discoveries are made in the lab, if they can’t be communicated well, how can they be used to advance the field and benefit patients? Dr. Pisetsky, the founding physician editor of The Rheumatologist, a professor of…
This session (12S114) at ACR Convergence 2023 will review the diagnostic approach to nonradiographic axial spondyloarthritis, with an emphasis on the role of imaging and recognition of its mimics. For your review—or a preview if you plan to catch the session on demand—our article will capture the highlights from Lianne Gensler, MD, Mark Hwang, MD,…
In this session at ACR Convergence 2023 (15W112), Ursula Fearon, PhD, Christopher Ritchlin, MD, MPH, and Jose Scher, MD, will highlight recent work that describes key processes in the pathophysiology of psoriatic arthritis, including perturbations in immune and stromal cells and the microbiome. Watch for our article for a snapshot of what these experts have…
The ACR journal, Arthritis & Rheumatology has introduced a new educational series, with the complement system first in focus. “This isn’t simplified immunology for trainees,” says Dr. Bucala. “It’s for everyone.”
On Oct. 5, Pfizer announced that Abrilada (adalimumab-afzb), its biosimilar to Humira (adalimumab), had received an interchangeable designation from the U.S. Food & Drug Administration (FDA).
Rheumatology giant Frederick Wolfe, MD, passed away Sept. 5, 2023, in Wichita, Kan. The rheumatology community mourns his loss. Fred was born July 1, 1936, in New York. He graduated from Queens College, N.Y., in 1958, and was a social worker for several years. He earned his medical degree in 1966 from the State University…